Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Wave Life Sciences (WVE) over the last 11 years, with Q3 2025 value amounting to $6.5 million.

  • Wave Life Sciences' Share-based Compensation rose 8329.09% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 7034.04%. This contributed to the annual value of $13.1 million for FY2024, which is 3416.03% up from last year.
  • As of Q3 2025, Wave Life Sciences' Share-based Compensation stood at $6.5 million, which was up 8329.09% from $6.2 million recorded in Q2 2025.
  • In the past 5 years, Wave Life Sciences' Share-based Compensation registered a high of $7.0 million during Q2 2022, and its lowest value of $2.3 million during Q3 2023.
  • Its 5-year average for Share-based Compensation is $3.9 million, with a median of $3.5 million in 2024.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 15532.7% in 2022, then tumbled by 6533.81% in 2023.
  • Quarter analysis of 5 years shows Wave Life Sciences' Share-based Compensation stood at $3.7 million in 2021, then dropped by 21.98% to $2.9 million in 2022, then decreased by 19.09% to $2.4 million in 2023, then surged by 37.93% to $3.2 million in 2024, then soared by 99.51% to $6.5 million in 2025.
  • Its Share-based Compensation was $6.5 million in Q3 2025, compared to $6.2 million in Q2 2025 and $5.0 million in Q1 2025.